A moderate response to plasmapheresis in nephrogenic systemic fibrosis
Nephrogenic systemic fibrosis (NSF) is a recently identified idiopathic cutaneous fibrosing disorder that occurs in the setting of renal failure. The disease initially called nephrogenic fibrosing dermopathy is closely linked to exposure to gadolinium-based contrast media used during magnetic resona...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2011-11-01
|
Series: | Clinics and Practice |
Subjects: | |
Online Access: | https://www.clinicsandpractice.org/index.php/cp/article/view/182 |
id |
doaj-1dc04ee7a1d442bd93c569198c31e15c |
---|---|
record_format |
Article |
spelling |
doaj-1dc04ee7a1d442bd93c569198c31e15c2021-04-02T12:24:40ZengMDPI AGClinics and Practice2039-72752039-72832011-11-011410.4081/cp.2011.e124117A moderate response to plasmapheresis in nephrogenic systemic fibrosisPelin Ustuner0Ozlem Karadag Kose1A. Tulin Gulec2Ozlem Ozen3Department of Dermatology, Faculty of Medicine, Baskent University, AnkaraDepartment of Dermatology, Faculty of Medicine, Baskent University, AnkaraDepartment of Dermatology, Faculty of Medicine, Baskent University, AnkaraDepartment of Pathology, Faculty of Medicine, Baskent University, AnkaraNephrogenic systemic fibrosis (NSF) is a recently identified idiopathic cutaneous fibrosing disorder that occurs in the setting of renal failure. The disease initially called nephrogenic fibrosing dermopathy is closely linked to exposure to gadolinium-based contrast media used during magnetic resonance imaging in patients with renal insufficiency. Although little is known about the pathogenesis of this disease, the increased expression of transforming growth factor-beta has been demonstrated recently. Herein, we present a case of NSF was partially treated due to a moderate and temporary response to plasmapheresis with no recurrence for 6 months, but returned at the end of 6th month.https://www.clinicsandpractice.org/index.php/cp/article/view/182nephrogenic fibrosing dermopathyplasmapheresistransforming growth factors. |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Pelin Ustuner Ozlem Karadag Kose A. Tulin Gulec Ozlem Ozen |
spellingShingle |
Pelin Ustuner Ozlem Karadag Kose A. Tulin Gulec Ozlem Ozen A moderate response to plasmapheresis in nephrogenic systemic fibrosis Clinics and Practice nephrogenic fibrosing dermopathy plasmapheresis transforming growth factors. |
author_facet |
Pelin Ustuner Ozlem Karadag Kose A. Tulin Gulec Ozlem Ozen |
author_sort |
Pelin Ustuner |
title |
A moderate response to plasmapheresis in nephrogenic systemic fibrosis |
title_short |
A moderate response to plasmapheresis in nephrogenic systemic fibrosis |
title_full |
A moderate response to plasmapheresis in nephrogenic systemic fibrosis |
title_fullStr |
A moderate response to plasmapheresis in nephrogenic systemic fibrosis |
title_full_unstemmed |
A moderate response to plasmapheresis in nephrogenic systemic fibrosis |
title_sort |
moderate response to plasmapheresis in nephrogenic systemic fibrosis |
publisher |
MDPI AG |
series |
Clinics and Practice |
issn |
2039-7275 2039-7283 |
publishDate |
2011-11-01 |
description |
Nephrogenic systemic fibrosis (NSF) is a recently identified idiopathic cutaneous fibrosing disorder that occurs in the setting of renal failure. The disease initially called nephrogenic fibrosing dermopathy is closely linked to exposure to gadolinium-based contrast media used during magnetic resonance imaging in patients with renal insufficiency. Although little is known about the pathogenesis of this disease, the increased expression of transforming growth factor-beta has been demonstrated recently. Herein, we present a case of NSF was partially treated due to a moderate and temporary response to plasmapheresis with no recurrence for 6 months, but returned at the end of 6th month. |
topic |
nephrogenic fibrosing dermopathy plasmapheresis transforming growth factors. |
url |
https://www.clinicsandpractice.org/index.php/cp/article/view/182 |
work_keys_str_mv |
AT pelinustuner amoderateresponsetoplasmapheresisinnephrogenicsystemicfibrosis AT ozlemkaradagkose amoderateresponsetoplasmapheresisinnephrogenicsystemicfibrosis AT atulingulec amoderateresponsetoplasmapheresisinnephrogenicsystemicfibrosis AT ozlemozen amoderateresponsetoplasmapheresisinnephrogenicsystemicfibrosis AT pelinustuner moderateresponsetoplasmapheresisinnephrogenicsystemicfibrosis AT ozlemkaradagkose moderateresponsetoplasmapheresisinnephrogenicsystemicfibrosis AT atulingulec moderateresponsetoplasmapheresisinnephrogenicsystemicfibrosis AT ozlemozen moderateresponsetoplasmapheresisinnephrogenicsystemicfibrosis |
_version_ |
1721569073487151104 |